Rating Rationale
May 31, 2019 | Mumbai
Valens Molecules Private Limited
Rated amount enhanced
 
Rating Action
Total Bank Loan Facilities Rated Rs.40 Crore (Enhanced from Rs.35 Crore)
Long Term Rating CRISIL BB/Stable (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its rating on the bank facilities of Valens Molecules Private Limited (VMPL) at 'CRISIL BB/Stable'.

The ratings continue to reflect the company's established market position in the bulk drug intermediates segment, backed by the promoters' extensive industry experience and established customer relationships, and its moderate financial risk profile. These strengths are partially offset by modest scale of operations and exposure to intense competition.

Key Rating Drivers & Detailed Description
Strengths:
* Established market position in the bulk drug intermediates segment, backed by promoters' extensive industry experience and established customer relationships:
VMPL's business risk profile benefits from the extensive industry experience of its promoters and healthy and longstanding relationships with key customers and suppliers. Backed by strong technical expertise in active pharmaceutical ingredients (APIs) and intermediaries, the promoters have introduced and developed new products over the years.

* Moderate financial risk profile: Gearing and networth were healthy at 0.96 time and Rs 41.88 crore, respectively, as on March 31, 2018. Net cash accrual to total debt and interest coverage ratios were at 0.05 time and 4 times, respectively, for fiscal 2018. The gearing and debt protection metrics are expected to weaken in fiscal 2018 due to debt-funded capital expenditure, but will remain comfortable.

Weaknesses:
* Modest scale of operations

Modest scale of operations (reflected in estimated revenue of Rs. 34 crore in fiscal 2019) in the fragmented pharmaceutical APIs industry limits the company's bargaining power with key customers and constrains its business risk profile.

* Exposure to intense competition and stringent regulatory framework in the bulk drugs industry
VMPL will remain susceptible to the intense competition and the stringent regulatory framework in the bulk drugs industry. While the Indian bulk drugs industry has a large number of standalone bulk drug manufacturers, most formulators are also backward integrated into bulk drug production. Large players with the ability to develop new and complex products have been able to insulate their profitability from pricing pressures.
Liquidity

Liquidity is adequate, with accrual expected at Rs 3.5-5.0 crore in the next 2 fiscals against annual debt obligation of Rs 3 crore. The company recently availed a cash credit limit of Rs 8 crore, which should support liquidity over the medium term. With commencement of operations at its Visakhapatnam unit, capital expenditure requirement is likely to be negligible over the medium term.

Outlook: Stable

CRISIL believes VMPL will continue to benefit from its promoters' extensive industry experience and its established relationships with customers and suppliers. The outlook may be revised to 'Positive' if revenue and profitability increase substantially, or if the company stabilises its ongoing project earlier than expected, resulting in higher cash accrual, while sustaining its healthy capital structure. The outlook may be revised to 'Negative' if revenue and profitability decline, or if there are time and cost overruns in the ongoing project, or if working capital requirement increases significantly, weakening the financial risk profile.

About the Company

Incorporated in 1995 as Posh Chemicals Pvt Ltd, VMPL got its present name in August 2016. Based in Hyderabad and promoted by Mr C S Ratna Prasad and his family members, the company manufactures bulk drug intermediates.

Key Financial Indicators
Particulars Unit 2018 2017
Revenue Rs. Cr. 26.31 24.17
Profit After Tax Rs. Cr. 0.96 0.58
PAT Margin % 3.7 2.4
Adjusted Debt/Adjusted Net worth Times 0.96 0.27
Interest coverage Times 4.09 4.83
 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon rate (%) Maturity date Issue size (Rs Cr) Rating assigned with outlook
NA Cash Credit NA NA NA 8 CRISIL BB/Stable
NA Long Term Loan NA NA Feb-2025 32 CRISIL BB/Stable
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  40.00  CRISIL BB/Stable      27-12-18  CRISIL BB/Stable  12-06-17  CRISIL BB+/Stable  23-05-16  CRISIL BBB-/Negative  CRISIL BBB-/Stable 
            31-10-18  CRISIL BB+/Stable (Issuer Not Cooperating)*           
Non Fund-based Bank Facilities  LT/ST          31-10-18  CRISIL A4+ (Issuer Not Cooperating)*  12-06-17  CRISIL A4+  23-05-16  CRISIL A3  CRISIL A3 
All amounts are in Rs.Cr.
*Issuer did not cooperate; based on best-available information
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 8 CRISIL BB/Stable Cash Credit 3 CRISIL BB/Stable
Long Term Loan 32 CRISIL BB/Stable Long Term Loan 32 CRISIL BB/Stable
Total 40 -- Total 35 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Framework for Assessing Information Adequacy Risk
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Sairam Nampalli
Rating Analyst - CRISIL Ratings
CRISIL Limited
B:+91 40 4032 8200
Sairam.Nampalli@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL